UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 498

Sortiert nach

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

Leukemia, 2012-05, Vol.26 (5), p.985-990

2012

Volltextzugriff (PDF)

Imatinib: a selective tyrosine kinase inhibitor

European journal of cancer (1990), 2002-09, Vol.38, p.S19-S27

2002

Volltextzugriff (PDF)

Midostaurin: a magic bullet that blocks mast cell expansion and activation

Annals of oncology, 2017-10, Vol.28 (10), p.2367-2376

2017

Volltextzugriff (PDF)

New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

Journal of medicinal chemistry, 2000-06, Vol.43 (12), p.2310-2323

2000

Volltextzugriff (PDF)

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Leukemia, 2016-02, Vol.30 (2), p.464-472

2016

Volltextzugriff (PDF)

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Cancer cell, 2005-02, Vol.7 (2), p.129-141

2005

Volltextzugriff (PDF)

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT

Haematologica (Roma), 2007-11, Vol.92 (11), p.1451-1459

2007

Volltextzugriff (PDF)

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

Cancer cell, 2003-05, Vol.3 (5), p.459-469

2003

Volltextzugriff (PDF)

Binding of the K+ channel opener [3H]P1075 in rat isolated aorta: relationship to functional effects of openers and blockers

Molecular pharmacology, 1993-03, Vol.43 (3), p.474-481

1993

Volltextzugriff (PDF)

Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis

Leukemia, 2008-03, Vol.22 (3), p.649-652

2008

Volltextzugriff (PDF)

Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas

Journal of medicinal chemistry, 1992-06, Vol.35 (12), p.2327-2340

1992

Volltextzugriff (PDF)

Egyptian ‘Funerary Cones’ from El-Moghraqa, Gaza

Antiquaries journal, 2004-09, Vol.84, p.319-333

2004

Volltextzugriff (PDF)

Synthesis of and radioligand binding studies with a tritiated pinacidil analog: receptor interactions of structurally different classes of potassium channel openers and blockers

Journal of medicinal chemistry, 1993-07, Vol.36 (14), p.2004-2010

1993

Volltextzugriff (PDF)

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

Cancer research (Chicago, Ill.), 2005-06, Vol.65 (11), p.4500-4505

2005

Volltextzugriff (PDF)

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Structure (London), 2005-06, Vol.13 (6), p.861-871

2005

Volltextzugriff (PDF)

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Blood, 2006-01, Vol.107 (2), p.752-759

2006

Volltextzugriff (PDF)

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

Blood, 2005-08, Vol.106 (3), p.996-1002

2005

Volltextzugriff (PDF)

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

Biochimica et biophysica acta, 2005-12, Vol.1754 (1), p.3-13

2005

Volltextzugriff (PDF)

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy

OncoTargets and therapy, 2018-01, Vol.11, p.175-182

2018

Volltextzugriff (PDF)

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Pharmacology & therapeutics (Oxford), 2002-02, Vol.93 (2), p.79-98

2002

Volltextzugriff (PDF)

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

Mini reviews in medicinal chemistry, 2004-03, Vol.4 (3), p.285

2004

Volltextzugriff (PDF)

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo

Blood, 2005-11, Vol.106 (9), p.3206-3213

2005

Volltextzugriff (PDF)

Prostaglandins, thromboxanes, leukotrienes, and related arachidonic acid metabolites

Natural product reports, 1984-01, Vol.1 (5), p.409-441

1984

Volltextzugriff (PDF)

Thrombin receptor antagonists: Structure-activity relationships for the platelet thrombin receptor and effects on prostacyclin synthesis by human umbilical vein endothelial cells

Biochemical pharmacology, 1990-01, Vol.39 (2), p.373-381

1990

Volltextzugriff (PDF)

Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitors

Journal of medicinal chemistry, 1987-09, Vol.30 (9), p.1588-1595

1987

Volltextzugriff (PDF)

1 – 25 von 498

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(403)
Mit Volltextzugriff
(436)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Physical Review. C, Nuclear Physics
(37)
Physical Review Letters
(33)
Physics Letters. B
(29)
The European Physical Journal. A, Hadrons And Nuclei
(29)
British Medical Journal
(11)
Bmj
(10)
Journal Of Medicinal Chemistry
(10)
Neuro-Oncology
(9)
Physical Review. C
(8)
Blood
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

Imatinib: a selective tyrosine kinase inhibitor

Midostaurin: a magic bullet that blocks mast cell expansion and activation

New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

Binding of the K+ channel opener [3H]P1075 in rat isolated aorta: relationship to functional effects of openers and blockers

Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis

Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas

Egyptian ‘Funerary Cones’ from El-Moghraqa, Gaza

Synthesis of and radioligand binding studies with a tritiated pinacidil analog: receptor interactions of structurally different classes of potassium channel openers and blockers

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo

Prostaglandins, thromboxanes, leukotrienes, and related arachidonic acid metabolites

Thrombin receptor antagonists: Structure-activity relationships for the platelet thrombin receptor and effects on prostacyclin synthesis by human umbilical vein endothelial cells

Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitors

Suchergebnisse filtern